Document is current
Any future updates will be listed below
-
Authors
Naito, Yoichi https://orcid.org/0000-0002-8490-9064
Kuboki, Yasutoshi https://orcid.org/0000-0003-3675-953X
Ikeda, Masafumi https://orcid.org/0000-0002-4050-2086
Harano, Kenichi https://orcid.org/0000-0002-0833-3489
Matsubara, Nobuaki https://orcid.org/0000-0002-9203-4245
Toyoizumi, Shigeyuki https://orcid.org/0000-0002-7011-5263
Mori, Yuko https://orcid.org/0000-0003-1919-2463
Hori, Natsuki https://orcid.org/0000-0003-4675-3975
Nagasawa, Takashi https://orcid.org/0000-0002-1600-1062
Kogawa, Takahiro https://orcid.org/0000-0003-3730-6591
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 30 January 2021
Accepted: 21 April 2021
First Online: 23 June 2021
Declarations
:
: The study protocol was approved by the Institutional Review Board and Ethics Committee at each investigational site and was conducted in accordance with the International Conference on Harmonisation Guidelines for Good Clinical Practice and the Declaration of Helsinki. All patients provided written informed consent prior to undergoing any study-specific procedure.
: Not applicable.
: Yoichi Naito has received lecture fees, honoraria, or other fees from Pfizer, Novartis, and Chugai and research funds from Roche. Yasutoshi Kuboki has received lecture fees, honoraria, or other fees from Taiho Pharmaceutical and research funds from Taiho Pharmaceutical, Takeda Pharmaceutical, Ono Pharmaceutical, AstraZeneca, Daichi-Sankyo, Boehringer Ingelheim, Incyte, Amgen KK, and Chugai Pharmaceutical. Masafumi Ikeda has received lecture fees, honoraria, or other fees from Novartis Pharma, Bayer, Eisai, Taiho Pharmaceutical, Eli Lilly Japan, and Chugai Pharmaceutical and research funds from Bayer, Yakult, ASLAN, Ono Pharmaceutical, Eisai, AstraZeneca, Chugai Pharmaceutical, Bristol Myers Squibb, Merck Serono, Novartis Pharma, Merck Sharp & Dome, and J-Pharma. Nobuaki Matsubara has received research funds from Pfizer Japan Inc. Shigeyuki Toyoizumi, Yuko Mori, Natsuki Hori, and Takashi Nagasawa are employees of Pfizer and report ownership interest in Pfizer.Kenichi Harano and Takahiro Kogawa have nothing to disclose.
